228 related articles for article (PubMed ID: 19443462)
1. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials.
Mitchell P; Korobelnik JF; Lanzetta P; Holz FG; Prünte C; Schmidt-Erfurth U; Tano Y; Wolf S
Br J Ophthalmol; 2010 Jan; 94(1):2-13. PubMed ID: 19443462
[TBL] [Abstract][Full Text] [Related]
2. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
Ferrara N; Damico L; Shams N; Lowman H; Kim R
Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
[TBL] [Abstract][Full Text] [Related]
3. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
[TBL] [Abstract][Full Text] [Related]
4. Ranibizumab: Phase III clinical trial results.
Rosenfeld PJ; Rich RM; Lalwani GA
Ophthalmol Clin North Am; 2006 Sep; 19(3):361-72. PubMed ID: 16935211
[TBL] [Abstract][Full Text] [Related]
5. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
6. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
Heier JS; Antoszyk AN; Pavan PR; Leff SR; Rosenfeld PJ; Ciulla TA; Dreyer RF; Gentile RC; Sy JP; Hantsbarger G; Shams N
Ophthalmology; 2006 Apr; 113(4):633.e1-4. PubMed ID: 16483659
[TBL] [Abstract][Full Text] [Related]
7. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
[TBL] [Abstract][Full Text] [Related]
8. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Rosenfeld PJ; Heier JS; Hantsbarger G; Shams N
Ophthalmology; 2006 Apr; 113(4):623.e1. PubMed ID: 16581423
[TBL] [Abstract][Full Text] [Related]
9. [Ranibizumab for treatment of exudative age-related macular degeneration--own experience].
Wykrota H; Gierek-Lapińska A; Trzciakowski K; Gajdzik-Gajdecka U
Klin Oczna; 2007; 109(10-12):402-9. PubMed ID: 18488382
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.
Regillo CD; Brown DM; Abraham P; Yue H; Ianchulev T; Schneider S; Shams N
Am J Ophthalmol; 2008 Feb; 145(2):239-248. PubMed ID: 18222192
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
[TBL] [Abstract][Full Text] [Related]
12. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
Boyer DS; Antoszyk AN; Awh CC; Bhisitkul RB; Shapiro H; Acharya NR;
Ophthalmology; 2007 Feb; 114(2):246-52. PubMed ID: 17270674
[TBL] [Abstract][Full Text] [Related]
13. Safety of ranibizumab therapy in wet AMD and the role of vascular endothelial growth factors in physiological angiogenesis.
Figurska M; Robaszkiewicz J; Wierzbowska J
Klin Oczna; 2010; 112(4-6):147-50. PubMed ID: 20825071
[TBL] [Abstract][Full Text] [Related]
14. Effect of ranibizumab retreatment frequency on neurosensory retinal volume in neovascular amd.
Keane PA; Chang KT; Liakopoulos S; Jivrajka RV; Walsh AC; Sadda SR
Retina; 2009 May; 29(5):592-600. PubMed ID: 19289984
[TBL] [Abstract][Full Text] [Related]
15. Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration.
Mantel I; Zografos L; Ambresin A
Ophthalmologica; 2008; 222(5):321-3. PubMed ID: 18617755
[TBL] [Abstract][Full Text] [Related]
16. Ranibizumab for treatment of choroidal neovascularization secondary to age-related macular degeneration.
Bhatnagar P; Spaide RF; Takahashi BS; Peragallo JH; Freund KB; Klancnik JM; Cooney MJ; Slakter JS; Sorenson JA; Yannuzzi LA
Retina; 2007 Sep; 27(7):846-50. PubMed ID: 17891007
[TBL] [Abstract][Full Text] [Related]
17. Morphological and functional analysis of the loading regimen with intravitreal ranibizumab in neovascular age-related macular degeneration.
Bolz M; Simader C; Ritter M; Ahlers C; Benesch T; Prünte C; Schmidt-Erfurth U
Br J Ophthalmol; 2010 Feb; 94(2):185-9. PubMed ID: 19692384
[TBL] [Abstract][Full Text] [Related]
18. Review of ranibizumab trials for neovascular age-related macular degeneration.
Patel RD; Momi RS; Hariprasad SM
Semin Ophthalmol; 2011 Nov; 26(6):372-9. PubMed ID: 22044335
[TBL] [Abstract][Full Text] [Related]
19. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients.
Brown DM; Regillo CD
Am J Ophthalmol; 2007 Oct; 144(4):627-37. PubMed ID: 17893015
[TBL] [Abstract][Full Text] [Related]
20. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
Cohen SY; Dubois L; Tadayoni R; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Guiberteau B; Quentel G
Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
